News Image

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

Provided By GlobeNewswire

Last update: Jul 18, 2025

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

Read more at globenewswire.com

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (9/5/2025, 8:00:02 PM)

After market: 10.3 +0.23 (+2.28%)

10.07

-0.62 (-5.8%)



Find more stocks in the Stock Screener

Follow ChartMill for more